| First Author | Havas D | Year | 2011 |
| Journal | J Alzheimers Dis | Volume | 25 |
| Issue | 2 | Pages | 231-43 |
| PubMed ID | 21403389 | Mgi Jnum | J:280595 |
| Mgi Id | MGI:6363392 | Doi | 10.3233/JAD-2011-101866 |
| Citation | Havas D, et al. (2011) A longitudinal study of behavioral deficits in an AbetaPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 25(2):231-43 |
| abstractText | Elucidating the age-dependent alterations in transgenic (Tg) mice overexpressing amyloid-beta protein precursor (AbetaPP) is important for understanding the pathogenesis of Alzheimer's disease (AD) and designing experimental therapies. Cross-studies have previously characterized some time-dependent behavioral and pathological alterations in AbetaPP Tg mice, however, a more comprehensive longitudinal study is needed to fully examine the progressive nature of behavioral deficits in these mice. In order to better understand the age- and gender-dependent progression of behavioral alterations, we performed a longitudinal study wherein Tg mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations under the regulatory control of the neuron specific murine (m)Thy-1 promoter (mThy1-hAbetaPP751) were behaviorally analyzed at 3 months and then re-tested at 6 and 9 months of age. The results show that there was an age-associated impairment in learning in the water maze task and habituation in the hole-board task. Motor coordination of the mThy1-hAbetaPP751 Tg mice was well-preserved throughout the investigated life span however, gender-specific deficits were observed in spontaneous activity and thigmotaxis. Neuropathologically, mThy1-hAbetaPP751 Tg mice displayed a progressive increase in the number of Abeta plaques and mean plaque size in the cortex and hippocampus from 3 to 6 and from 6 to 9 months of age. Taken together, these results indicate that the mThy1-hAbetaPP751 Tg mice model AD from the early onset of the disease through to later stages, allowing them to be utilized at numerous points during the timeline for drug test designs. |
